HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Epidemiology of Shock in Contemporary Cardiac Intensive Care Units.

Abstract
Background Clinical investigations of shock in cardiac intensive care units (CICUs) have primarily focused on acute myocardial infarction (AMI) complicated by cardiogenic shock (AMICS). Few studies have evaluated the full spectrum of shock in contemporary CICUs. Methods and Results The Critical Care Cardiology Trials Network is a multicenter network of advanced CICUs in North America. Anytime between September 2017 and September 2018, each center (n=16) contributed a 2-month snap-shot of all consecutive medical admissions to the CICU. Data were submitted to the central coordinating center (TIMI Study Group, Boston, MA). Shock was defined as sustained systolic blood pressure <90 mm Hg with end-organ dysfunction ascribed to the hypotension. Shock type was classified by site investigators as cardiogenic, distributive, hypovolemic, or mixed. Among 3049 CICU admissions, 677 (22%) met clinical criteria for shock. Shock type was varied, with 66% assessed as cardiogenic shock (CS), 7% as distributive, 3% as hypovolemic, 20% as mixed, and 4% as unknown. Among patients with CS (n=450), 30% had AMICS, 18% had ischemic cardiomyopathy without AMI, 28% had nonischemic cardiomyopathy, and 17% had a cardiac cause other than primary myocardial dysfunction. Patients with mixed shock had cardiovascular comorbidities similar to patients with CS. The median CICU stay was 4.0 days (interquartile range [IQR], 2.5-8.1 days) for AMICS, 4.3 days (IQR, 2.1-8.5 days) for CS not related to AMI, and 5.8 days (IQR, 2.9-10.0 days) for mixed shock versus 1.9 days (IQR, 1.0-3.6) for patients without shock ( P<0.01 for each). Median Sequential Organ Failure Assessment scores were higher in patients with mixed shock (10; IQR, 6-13) versus AMICS (8; IQR, 5-11) or CS without AMI (7; IQR, 5-11; each P<0.01). In-hospital mortality rates were 36% (95% CI, 28%-45%), 31% (95% CI, 26%-36%), and 39% (95% CI, 31%-48%) in AMICS, CS without AMI, and mixed shock, respectively. Conclusions The epidemiology of shock in contemporary advanced CICUs is varied, and AMICS now represents less than one-third of all CS. Despite advanced therapies, mortality in CS and mixed shock remains high. Investigation of management strategies and new therapies to treat shock in the CICU should take this epidemiology into account.
AuthorsDavid D Berg, Erin A Bohula, Sean van Diepen, Jason N Katz, Carlos L Alviar, Vivian M Baird-Zars, Christopher F Barnett, Gregory W Barsness, James A Burke, Paul C Cremer, Jennifer Cruz, Lori B Daniels, Andrew P DeFilippis, Affan Haleem, Steven M Hollenberg, James M Horowitz, Norma Keller, Michael C Kontos, Patrick R Lawler, Venu Menon, Thomas S Metkus, Jason Ng, Ryan Orgel, Christopher B Overgaard, Jeong-Gun Park, Nicholas Phreaner, Robert O Roswell, Steven P Schulman, R Jeffrey Snell, Michael A Solomon, Bradley Ternus, Wayne Tymchak, Fnu Vikram, David A Morrow
JournalCirculation. Cardiovascular quality and outcomes (Circ Cardiovasc Qual Outcomes) Vol. 12 Issue 3 Pg. e005618 (03 2019) ISSN: 1941-7705 [Electronic] United States
PMID30879324 (Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural)
Topics
  • Aged
  • Coronary Care Units
  • Female
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (diagnosis, epidemiology, mortality, therapy)
  • North America (epidemiology)
  • Organ Dysfunction Scores
  • Prognosis
  • Registries
  • Risk Assessment
  • Risk Factors
  • Shock, Cardiogenic (diagnosis, epidemiology, mortality, therapy)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: